Recent News

• 11.05.2026 - aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update
• 10.29.2026 - aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
• 10.29.2026 - Efzofitimod Versus Placebo in Patients with Pulmonary Sarcoidosis (EFZO-FIT): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
• 10.27.2026 - aTyr Pharma Announces One-for-40 Reverse Stock Split
• 10.19.2026 - aTyr Pharma Announces Research Collaboration with Montefiore Einstein
• 10.13.2026 - Natural Asp-tRNA Synthetase Fragment Targets Myofibroblasts to Abrogate Tissue Fibrosis Journal of Biological Chemistry, 2026
• 10.13.2026 - aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
• 09.24.2026 - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
• 09.01.2026 - aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
• 08.07.2026 - aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Recent Filings

• 11.02.2026 - EX-99.1 EX-99.1
• 11.02.2026 - 8-K Current report
• 10.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.16.2026 - 144 Report of proposed sale of securities
• 10.15.2026 - 144 Report of proposed sale of securities
• 10.15.2026 - 144 Report of proposed sale of securities
• 10.14.2026 - 144 Report of proposed sale of securities
• 10.09.2026 - 8-K Current report
• 09.18.2026 - 144 Report of proposed sale of securities